These results suggest that pharmacological IL17A blockade can enhance immune activation and contribute to the anti‐tumour effect of the ENO1 DNA vaccine, even in a rapidly progressing orthotopic model where the vaccine alone shows limited efficacy. Here, ENO1 is linked to neoplasm.